PATENT CLAIM ANALYSIS

Application Number: 15887299
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["424", "139100"]

Abstract:
The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.

Claim (Index 22):
The anti-sclerostin antibody according to  claim 21  where:\n (i) the different treatment is an anti-resorptive, optionally a bisphosphonate; and/or \n (ii) the subject is one who has also been administered the different treatment prior to step (a).

Metadata:
- Claim Count in Document: 1.0
- Percentile: 88.0
- Lexical Diversity: 2.16667
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13934433', '13090075', '13860954', '13090058', '12212327']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7427924787266854
- 35 USC 102 Novelty (BERT): 0.6341623804228956
- Combined Prediction Score: 0.7319294688963065
- Mean Citation Score: 509.410518
- Max Citation Score: 712.5443
- Similarity Product: 512.0591192788661

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test